A
Adrian Covic
Researcher at Grigore T. Popa University of Medicine and Pharmacy
Publications - 605
Citations - 20724
Adrian Covic is an academic researcher from Grigore T. Popa University of Medicine and Pharmacy. The author has contributed to research in topics: Kidney disease & Population. The author has an hindex of 73, co-authored 570 publications receiving 17379 citations. Previous affiliations of Adrian Covic include Romanian Academy & Istanbul Medeniyet University.
Papers
More filters
Journal ArticleDOI
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy
Danilo Fliser,Maurice Laville,Adrian Covic,Denis Fouque,Raymond Vanholder,Laurent Juillard,Wim Van Biesen +6 more
TL;DR: The present document will deal with the diagnosis and prevention of AKI, and contrast-induced nephropathy (CIN) (Sections 1–4 of the KDIGO document), and other chapters will be discussed in a separate position statement.
Journal ArticleDOI
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement
Francesco Locatelli,Peter Bárány,Adrian Covic,Angel L.M. de Francisco,Lucia Del Vecchio,David Goldsmith,Walter H. Hörl,Gérard M. London,Raymond Vanholder,Wim Van Biesen +9 more
TL;DR: The group concentrated only on those guidelines which the group considered worth amending or adapting, and all guidelines not specifically mentioned are fully endorsed.
Journal ArticleDOI
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
Alberto Ortiz,Adrian Covic,Danilo Fliser,Denis Fouque,David Goldsmith,Mehmet Kanbay,Francesca Mallamaci,Ziad A. Massy,Ziad A. Massy,Patrick Rossignol,Raymond Vanholder,Andrzej Wiecek,Carmine Zoccali,Gérard M. London +13 more
TL;DR: Policy changes to improve access to renal replacement therapy should be combined with research into low-cost renal replacement Therapy and optimum clinical care, which should include multifaceted approaches simultaneously targeting several of the putative contributors to increased mortality.
Journal ArticleDOI
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions.
Mehmet Kanbay,Adem Özkara,Yusuf Selcoki,Bunyamin Isik,Faruk Turgut,Nuket Bavbek,Ebru Uz,Ali Akcay,Ramazan Yigitoglu,Adrian Covic +9 more
TL;DR: In this paper, the benefits of allopurinol treatment in hyperuricemic patients with normal renal function were investigated for patients with glomerular filtration rate (GFR) > 60 ml/min.
Journal ArticleDOI
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration.
Luuk B. Hilbrands,Raphaël Duivenvoorden,Priya Vart,Priya Vart,Casper F. M. Franssen,Marc H Hemmelder,Kitty J Jager,Lyanne M. Kieneker,Marlies Noordzij,Michelle J Pena,Hanne de Vries,David Arroyo,Adrian Covic,Marta Crespo,Eric Goffin,Mahmud Islam,Ziad A. Massy,Ziad A. Massy,Nuria Montero,João Pedro Oliveira,Ana Roca Muñoz,J Emilio Sanchez,Sivakumar Sridharan,Rebecca Winzeler,Ron T. Gansevoort +24 more
TL;DR: The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty.